Bench2Bedside spoke with EGB Ventures founder and CEO William Garner, M.D., about how his background in medicine and finance shapes company building, the opportunities and challenges of Australia’s biotechnology market, and recent progress at portfolio companies Entropy Neurodynamics (ASX:ENP) and...
Bench2Bedside spoke with GuideStar CEO Mike Dolphin, Ph.D., about the overlooked burden of accidental dural puncture, and how his outsider’s perspective as an aerospace engineer helped him challenge a long-standing standard of care, leading to the development of EpiZact....
Bench2Bedside spoke with ARC Medical CEO Chris Springate about the limitations of existing adhesion barriers, the company’s differentiated approach, and the clinical programs underway to evaluate its technology in orthopedic and abdominopelvic surgery....
Bench2Bedside spoke with Steven Damon, CEO of Micron Biomedical about the companies “push button”, needle-free drug delivery technology, and how it can bring life-saving medicines and vaccines to some of the world’s most remote regions....
Bench2Bedside recently sat down with Eileen Heffernan, Celltaxis' Chief Executive Officer and co-founder, to discuss the Company's mission to transform the treatment of lymphatic disease, the science behind its therapeutic approach, and why she believes Celltaxis is uniquely positioned to...
In this Bench2Bedside conversation, we speak with CEO Andrew Hall about Consano Bio’s transition into the clinic, marked by first patient dosed in its Phase 1 study, and the implications for treating nerve-related pain....
In this interview, with Bench2Bedside, Dr. Haifeng Chen, CEO of AAVivo, Inc., discusses how his company aims to bypass these hurdles. By shifting from a manufacturing mindset to an engineering one, Dr. Chen outlines a revolutionary vision to turn the...
In this Bench2Bedside conversation, Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics, discusses the company’s recent Nasdaq direct listing, the value potential of its Bisphosphocin® antimicrobial platform, and its lead candidate Nu-3 for mildly infected diabetic foot ulcers (iDFU)....
In this Bench2Bedside conversation, Enveric’s CEO, Joseph Tucker, Ph.D., discusses the company’s lead candidate, EB-003, the potential of dual-receptor engagement, and the hope of bringing solutions to difficult-to-treat mental health disorders....
As the New Year kicks off and the biotech world makes the annual pilgrimage to San Francisco, Michael Brinkman, Managing Director at Jefferies, gives his views on the unusually strong biotech and specialty pharma market moving into 2026....